Insmed Incorporated (INSM )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol INSM
- Company Insmed Incorporated
- Price $131.1
- Changes Percentage -1.09
- Change -1.45
- Day Low $126.44
- Day High $135.06
- Year High $212.75
- Year Low $90.39
- Market Cap $22,806,645,440
- Price Avg 50 EMA (D) $105.52
- Price Avg 200 EMA (D) $148.83
- Exchange NASDAQ
- Volume 424,183
- Average Volume 3,882,793
- Open $135
- Previous Close $132.55
- EPS -5.75
- PE -18.30
- Earnings Announcement 2026-08-06 04:00:00
- Shares Outstanding $216,752,000
Company brief: INSMED INCORPORATED (INSM )
- Healthcare
- Biotechnology
- Mr. William H. Lewis J.D., M.B.A.
- https://www.insmed.com
- US
- N/A
- 06-01-2000
- US4576693075
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.